HLA-B alleles confer susceptibility to sulfasalazine-induced severe cutaneous adverse reactions.

J Allergy Clin ImmunolMay 4, 2026 (epub)
Clinical ResearchAllergy & ImmunologyMedical Genetics

Chuang-Wei Wang, Wei-Ti Chen, Chun-Bing Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis investigated the genetic predisposition to sulfasalazine-induced severe cutaneous adverse reactions (SCARs) in Asian populations. The study identified multiple HLA-B alleles associated with SCARs, with 84.8% sensitivity in predicting these reactions in the Chinese population. The analysis included 105 cases and 23,743 controls across several Asian countries.

Key findings

  • HLA-B alleles B∗39:01, B∗13:01, and B∗38:02 are significantly associated with sulfasalazine-induced SCARs.
  • The study found 84.8% sensitivity in predicting SCARs using HLA-B alleles in the Chinese population.
  • Functional assays indicated increased granulysin release from CD8 + T cells in affected patients.

Why it matters

Understanding genetic predispositions to drug reactions can help clinicians identify at-risk patients, potentially guiding safer prescribing practices for sulfasalazine and similar medications.

Source

PubMed · PMID 42092593

Published in J Allergy Clin Immunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Allergy & Immunology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.